Patents by Inventor Imran Alibhai

Imran Alibhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240033234
    Abstract: The present disclosure, in part, is directed to compositions comprising a compound of formula (I): wherein the compositions are substantially free of an impurity, processes of producing thereof, and uses thereof.
    Type: Application
    Filed: August 9, 2023
    Publication date: February 1, 2024
    Inventors: Imran Alibhai, Sofia de Achaval, Alan Millar
  • Publication number: 20240018172
    Abstract: Provided herein, in certain embodiments, are compounds of Formula I: or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
    Type: Application
    Filed: August 9, 2023
    Publication date: January 18, 2024
    Inventors: Imran Alibhai, Sofia de Achaval, Jeffrey Larson, Brad Henke
  • Publication number: 20230285334
    Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
    Type: Application
    Filed: November 28, 2022
    Publication date: September 14, 2023
    Inventors: Imran Alibhai, Sofia de Achaval, Beverly C. Langevin, Tian Zhou
  • Publication number: 20230077280
    Abstract: Embodiments of the disclosure encompass methods of treating insulin resistance in an individual in need thereof by administering one or more STAT3 inhibitors to the individual. In specific aspects, the methods allow for reversing insulin resistance in individuals. The STAT3 inhibitor may be one or more particular small molecules encompassed herein.
    Type: Application
    Filed: December 3, 2020
    Publication date: March 9, 2023
    Inventors: William E. Mitch, Liping Zhang, David J. Tweardy, Imran Alibhai, Sofia de Achaval
  • Patent number: 11547683
    Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: January 10, 2023
    Assignee: Tvardi Therapeutics, Inc.
    Inventors: Imran Alibhai, Sofia De Achaval, Beverly C. Langevin, Tian Zhou
  • Publication number: 20210322347
    Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 21, 2021
    Inventors: Imran Alibhai, Sofia De Achaval, Beverly C. Langevin, Tian Zhou
  • Patent number: 11077077
    Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: August 3, 2021
    Assignee: Tvardi Therapeutics, Inc.
    Inventors: Imran Alibhai, Sofia De Achaval, Beverly C. Langevin, Tian Zhou
  • Publication number: 20210228512
    Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 29, 2021
    Inventors: Imran Alibhai, Sofia De Achaval, Beverly C. Langevin, Tian Zhou